Evidence map›Paper›PMID 35225467›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Circulating Cell Free DNA and DNA Integrity Index as Discriminating Tools between Breast Cancer and Benign Breast Disease.

Rania Elhelaly, Narmen Effat, Mohamed Abd El-Fattah Hegazy, Khaled Abdelwahab, Omar Hamdy, Ekbal M Abo Hashem, Rasha R Elzehery

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rania ElhelalyDepartment of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Narmen EffatDepartment of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed Abd El-Fattah HegazyDepartment of Oncological Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Khaled AbdelwahabDepartment of Oncological Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Omar HamdyDepartment of Oncological Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ekbal M Abo HashemDepartment of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Rasha R ElzeheryDepartment of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEarly diagnosis of cancer remains a great challenge in the field of laboratory medicine. We investigated the ability of ccf DNA and DNA integrity index (DNA II) in differentiating benign from malignant breast diseases.

methodsSerum samples were collected from 50 patients with benign breast disease (BBD) and 50 newly diagnosed breast cancer (BC) patients, in addition to 50 control women. VEGF was measured by ELISA, while Real-time q-PCR was used to measure ccf DNA concentrations and to assess the concentrations of ALU repeats, both short fragments (115 bp) and long fragments (247 bp), then DNA II was calculated (all were done before and after radical mastectomy).

resultsBC group showed significantly higher ccf DNA concentrations and DNA II compared to BBD and control groups, meanwhile, no statistically significant differences were found between BBD and control groups. Ccf DNA concentrations decreased significantly after surgery (P <0.001). Good AUC was found for ccf DNA (AUC=0.860), fair AUC was found for DNA II (AUC=0.727), while VEGF AUC failed to discriminate between BBD and BC cases.

conclusionccf DNA and DNA II could be used as excellent molecular biomarkers for early diagnosis of BC and for monitoring the efficiency of therapy in such patients. Utilizing these molecular markers would improve both the healthcare and economic burden of malignancy.

Indexed as

BiomarkersBreast DiseasesBreast NeoplasmsCase-Control StudiesCell-Free Nucleic AcidsDiagnosis, DifferentialFemaleGenetic MarkersGenetic TestingHumansMastectomyMiddle AgedPredictive Value of TestsVascular Endothelial Growth Factor ABiomarkersCell-Free Nucleic AcidsGenetic MarkersVascular Endothelial Growth Factor AVEGFA protein, humanBenign Breast Diseasebreast cancerccf DNADNA integrity index

Identifiers

PMID35225467
PMCPMC9272613
OpenAlexW4214728649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.